Compare Crown Castle International Corp (CCI) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crown Castle International Corp vs Cassava Sciences Inc — how do they compare? Crown Castle International Corp trades at $79.87 (market cap $34.50B), while Cassava Sciences Inc trades at $1.09 (market cap $52.66M). The key difference: Crown Castle International Corp is far larger — about 655.1× Cassava Sciences Inc's market cap, and Crown Castle International Corp pays a 5.38% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| CCI | FLNA | |
|---|---|---|
Market Cap | $34.50B | $52.66M |
Sector | Real Estate | Health |
52-Week High | $113.91 | $4.64 |
52-Week Low | $74.92 | $1.09 |
Enterprise Value | $64.33B | -$33.92M |
Dividend Yield | 5.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Crown Castle (CCI) trades at $79.84, up 0.23% on the day, with a bearish technical signal from moving averages. The company reported mixed Q1 2026 earnings, missing EPS estimates, but maintains strong profitability with a 73.82% gross margin. Recent news highlights its pure-play U.S. tower focus and upcoming Q2 2026 earnings call on July 22, 2026.
CCI presents a turnaround opportunity with analyst consensus targeting $97.33, implying 22% upside, but faces risks from high debt levels and volatile earnings. The stock's negative equity and bearish technicals warrant caution despite attractive dividend yield and cost reduction initiatives.
FLNA trades at $1.15, down 2.54% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company continues to report losses, with a net income of -$90.97M in 2025 and negative cash flow, though it has beaten EPS estimates for the last three quarters. Recent news highlights ongoing development in its TSC-related epilepsy therapies.
Despite consistent earnings beats, FLNA's negative profitability and cash burn pose significant risks. Analyst sentiment is positive with a 66.7% buy rating, but the stock's outlook depends heavily on clinical success and future funding. Investors should weigh the high-risk, high-reward nature of this biotech play.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crown Castle International Corp
Crown Castle International owns and leases roughly 40,000 cell towers in the United States. It also owns more than 85,000 route miles of fiber. It leases space on its towers to wireless service providers, which install equipment on the towers to support their wireless networks. The company's fiber is primarily leased by wireless service providers to set up small-cell network infrastructure and by enterprises for their internal connection needs. Crown Castle's towers and fiber are predominantly located in the largest U.S. cities. The company has a very concentrated customer base, with more than 70% of its revenue coming from the big three U.S. mobile carriers. Crown Castle operates as a real estate investment trust.
Read more on CCI →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
